Several groundbreaking therapies are revolutionizing glucose care, with Retatrutide, Cagrillintide, Tirzepatide, and Semaglutide being highlighted leading candidates. Retatrutide, a double GIP and GLP-1 site activator, demonstrates remarkable body mass decrease coupled with enhanced blood sugar regulation. Cagrillintide, a GLP-1 activator, is curre